Depending on whom you ask, we are either in the early stages of, somewhat immersed in, or already fully immersed in Industry 4.0, the fourth industrial revolution. Industry 4.0 incorporates artificial ...

Annex 22 marks a paradigm shift in pharmaceutical manufacturing, not only because it closes the longstanding “AI grey zone” ...

Researchers milling around in a wide-open laboratory with lots of machines and computers. Scientists in Recursion Pharmaceuticals' automated high-throughput screening laboratory in Salt Lake City, ...

AI powers digital twins of cells/molecules, speeding early drug discovery and cutting trial-and-error work. Read more here.

AI has been a hot topic in the pharmaceutical industry, and the latest ChatGPT hype is fueling even more conversations. Right now, there’s a bifurcation of attitudes, with some scientists excited ...

The explosion in the sophistication and adoption of artificial intelligence has already seen software that can generate text and images based on simple cues, as well as edit videos and find patterns ...

While it’s widely accepted that the pharma industry is innovative in R&D, it is also true that it can be slow at embracing technological revolutions. Many people have criticized pharma companies for ...

Large-language models are excellent for general-use AI systems, but they don’t understand pharmaceutical companies’ ...

Scientists have long been challenged by the complex process of drug discovery and development, with investments that often go unrewarded. However, with the advancement of experimental technology and ...

HYDERABAD, India--(BUSINESS WIRE)--Aurigene Pharmaceutical Services Limited (Aurigene), a contract research, development, and manufacturing services organization and a Dr. Reddy’s Laboratories company ...

Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.

LONDON (Reuters) - The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 ...